The Effects of Dietary Fibres on Metabolic Health and the Gut Microbiome
- Conditions
- DietHealthySystemic Inflammatory Response
- Interventions
- Dietary Supplement: PectinDietary Supplement: Maltodextrin
- Registration Number
- NCT06580132
- Lead Sponsor
- Elizabeth Simpson
- Brief Summary
The study involves intake of dietary supplements, which are commonly found in the UK diet (not pharmacological agents) to test their effects on inflammation in the body and gut microbiome composition. Study subjects will be healthy volunteers recruited from the University and local population and will be asked to attend the laboratory on 2 occasions; before and after 4-week' supplementing the diet daily with either the dietary fibres (the current trial focussed on pectin) or placebo (maltodextrin). At each study visit (\~3hrs), participants will be asked to provide a stool and blood sample and will have blood pressure measured. In the week before each study visit, participants will record their food intake.
- Detailed Description
The overall aim of the proposed project is to unlock the effect of dietary fibres (i.e. LM Pectin) on anti-inflammatory and cardioprotective metabolic responses via the modulation of the gut microbiome and SCFAs production.
Specific Aim 1: To deliver a wealth of molecular data, including effect sizes, on the physiological effects of dietary fibres on the changes in the composition and function of the gut microbiome and changes in the metabolomic and physiological profile of an individual.
Specific Aim 2: To investigate the mechanisms whereby the gut microbiome modulates crucial physiological parameters such, blood glucose regulation, hunger and appetite, immune function markers in response to the anti-inflammatory effects of the gut microbiome.
30 healthy, non-obese volunteers will be recruited following a successful medical screening. Between recruitment and first study visit, and in the final week of the 4-week intervention (before the second study visit), participants will be asked to complete a dietary record (4 days), to collect a stool sample on the day before the study visit and to fast from midnight the night before this visit.
At both study visits, participants will have weight, hip/waist circumference and blood pressure measured. They will be asked to complete some questionnaires. After completion of the first study day, participants will be randomised to receive either the dietary fibre or placebo powder. They will be given the blinded products portioned in individual sachets, with instructions to add the contents of one sachet a day to juice, smoothies or water and to consume immediately. Study visit 2 will be scheduled at the end of the 4 week 'dosing' period.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 19
- Participant is willing and able to give informed consent for participation in the study
- Participant eligibility includes those aged >18 years who have a body mass index (BMI) between 18.5 and 39.9 kg/m2
The participant may not enter the study if ANY of the following apply:
- Have psychosocial or gastrointestinal (e.g. malabsorptive conditions such as IBS/IBD, coeliac)
- Are taking the following medications: immunosuppressants, amiodarone and/or perhexiline
- Are currently following or anticipated to commence a specialised commercially available weight loss diet and/or program/ taking prebiotic supplements
- Pregnant or breastfeeding
- History or current psychiatric illness
- History or current neurological condition (e.g. epilepsy)
- Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Fibre arm (Pectin) Pectin 20g of pectin was provided to healthy volunteers for 4 weeks. Maltodextrin Maltodextrin 10g of maltodextrin was provided to healthy volunteers for 4 weeks
- Primary Outcome Measures
Name Time Method Change in microbiome profile 4 weeks Change in microbiome profile, assessed using 16s RNA sequencing analysis of faecal samples provided pre and post the 4-week intervention period
Change in inflammatory profile 4 weeks Change in circulating markers of inflammation measured by ELISAs in serum samples collected pre and post the 4-week intervention period.
Changes in short chain fatty acids (SCFAs) 4 weeks Change in serum SCFAs measured by mass spectrometry pre and post the 4-week intervention period
- Secondary Outcome Measures
Name Time Method Change in Short Form Health Survey (SF12) Questionnaire aggregated normalised 'physical' score 4 weeks Change in 'SF12' Questionnaire aggregated 'physical' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better physical wellbeing; measured pre and post intervention
Change in systolic blood pressure (lying to standing) pre intervention 4 minutes Change in systolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at pre-intervention study visit
Change in systolic blood pressure (lying to standing) post intervention 4 minutes Change in systolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at post-intervention study visit
Change in diastolic blood pressure (lying to standing) pre intervention 4 minutes Change in diastolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at pre-intervention study visit
Change in diastolic blood pressure (lying to standing) post intervention 4 minutes Change in diastolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at post-intervention study visit
Change in Short Form Health Survey (SF12) Questionnaire aggregated normalised 'mental' score 4 weeks Change in 'SF12' Questionnaire aggregated 'mental' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better mental wellbeing; measured pre and post intervention
Change in Pittsburgh Sleep Quality Index (PSQI) 4 weeks Change in PSQI score (min score 0, max 21), measured pre and post the 4-week intervention, with higher score indicating poorer sleep quality
Change in Hospital Anxiety and Depression Score (HADS) 4 weeks Change in anxiety score (min score 0, max 3 with higher score indicating higher anxiety like symptoms), and depression score (min 3, max 0 with lower the scores indicating higher depression like symptoms) measured pre and post the 4-week intervention.
Trial Locations
- Locations (1)
University of Nottingham
🇬🇧Nottingham, United Kingdom